IRCT2012120711647N1 IRCT 2013-03-20 Vice chancellor for research, Tehran University of Medical Sciences The effect of bevacizumab on success of trabeculectomy in glaucoma patients Comparison of success of trabeculectomy in glaucoma patients treated with trabeculectomy alone versus adjunctive intracameral bevacizumab-combined trabeculectomy: A clinical trial 2013-01-28 anticipated 60 Complete https://irct.ir/trial/11822 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: The reason for this study being double-blind is: The investigator (the surgeon who performs trabeculectomies) is blinded, because at the end of operation he takes a syringe containing 0.05 ml of a clear liquid, but he does not know what is the liquid (either bevacizumab or balanced salt solution). The two mentioned liquids have similar appearance. However, a nurse who prepares the syringe with 0.05 ml liquid is told to fill it with either bevacizumab or balanced salt solution, and this information is recorded but not provided to the surgeon who performs trabeculectomies and the physician who visits the patients in the follow up period. The patient is also blinded to what he/she receives. The informed consent states that they either receive placebo or the drug bevacizumab, which is chosen by random. 2 Primary open-angle glaucoma. Intervention 1: Intervention 1: single injection of 1.25 mg (0.05 ml; concentration 25 mg/ml) bevacizumab (monoclonal antibody against VEGF; trade name Avastin, Genentech/Roche, San Francisco, CA) in the anterior chamber at termination of trabeculectomy surgery. Intervention 2: Intervention 2: single injection of placebo (0.05 ml balanced salt solution) in the anterior chamber at termination of trabeculectomy surgery.